Literature DB >> 19505085

Comprehensive profiling of the cell surface proteome of Sy5Y neuroblastoma cells yields a subset of proteins associated with tumor differentiation.

Jacob Garcia1, Vitor Faca, Jason Jarzembowski, Qing Zhang, Julie Park, Samir Hanash.   

Abstract

Neuroblastoma tumors are derived from the neural crest and exhibit substantial phenotypic heterogeneity and various degrees of differentiation and maturation. The identification of new cell surface markers in neuroblastoma has relevance to disease classification and therapy. As a means to categorize neuroblastomas based on cell surface protein expression, we have obtained a comprehensive profile of the cell surface proteome of the MYCN nonamplified SH-SY5Y neuroblastoma cell line. Biotinylated cell surface proteins were captured using an avidin affinity column, fractionated by reversed-phase chromatography and subjected to in-depth analysis by LC-MS/MS. An extensive list of proteins was established and a subset of surface membrane proteins was assessed by immunohistochemistry in a set of neuroblastoma tissue microarrays. Among identified proteins tested, NCAM and CD147 exhibited increased expression in poorly differentiated tumors (p < 0.01 and <0.03, respectively). CD147 expression was previously associated with aggressive carcinomas but has not been described in neuroblastoma. This comprehensive neuroblastoma cell surface profile has identified novel potential markers for neuroblastoma classification and novel potential targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505085     DOI: 10.1021/pr800964v

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  8 in total

1.  Surface proteome of "Mycobacterium avium subsp. hominissuis" during the early stages of macrophage infection.

Authors:  Michael McNamara; Shin-Cheng Tzeng; Claudia Maier; Li Zhang; Luiz E Bermudez
Journal:  Infect Immun       Date:  2012-03-05       Impact factor: 3.441

2.  Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma.

Authors:  Qing-Rong Chen; Young K Song; Li-Rong Yu; Jun S Wei; Joon-Yong Chung; Stephen M Hewitt; Timothy D Veenstra; Javed Khan
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

3.  Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens.

Authors:  Petr G Lokhov; Elena E Balashova
Journal:  J Cancer       Date:  2010-11-29       Impact factor: 4.207

Review 4.  Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC).

Authors:  Petr G Lokhov; Elena E Balashova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Targeting Neuroblastoma Cell Surface Proteins: Recommendations for Homology Modeling of hNET, ALK, and TrkB.

Authors:  Yazan Haddad; Zbyněk Heger; Vojtech Adam
Journal:  Front Mol Neurosci       Date:  2017-01-20       Impact factor: 5.639

Review 6.  Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy.

Authors:  Giulia Peppino; Roberto Ruiu; Maddalena Arigoni; Federica Riccardo; Antonella Iacoviello; Giuseppina Barutello; Elena Quaglino
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

7.  Analysis of SARS-CoV-2 infection associated cell entry proteins ACE2, CD147, PPIA, and PPIB in datasets from non SARS-CoV-2 infected neuroblastoma patients, as potential prognostic and infection biomarkers in neuroblastoma.

Authors:  Brandon Bergsneider; Elise Bailey; Yusuf Ahmed; Namrata Gogineni; Derek Huntley; Ximena Montano
Journal:  Biochem Biophys Rep       Date:  2021-07-19

8.  A highly predictive autoantibody-based biomarker panel for prognosis in early-stage NSCLC with potential therapeutic implications.

Authors:  Akshay J Patel; Ti-Myen Tan; Alex G Richter; Babu Naidu; Jonathan M Blackburn; Gary W Middleton
Journal:  Br J Cancer       Date:  2021-11-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.